Exploring the advantages of ready-to-use lipid-based gene delivery for gene-modified cell therapy

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

Attend this webinar to explore a non-viral alternative for ex vivo transfection of immune and stem cells, designed to overcome the limitations of traditional gene delivery methods. Learn how innovative lipid-based gene delivery offers key advantages for gene-modified cell therapies (GMCTs), including simplicity of use, cost-efficiency, high efficacy and enhanced cell health and growth, compared to viral vectors and/or electroporation.

Case study data will be presented detailing firsthand experience with the technology in a head-to-head comparison with electroporation for TRAC knockout in T cells, highlighting its ease of use and cost-efficiency, and potential to reshape the future of GMCT development.

Attend this webinar to learn about:

• Key advantages of lipid-based delivery approaches for ex vivo transfection of immune and stem cells, including accessibility, cost-efficiency and cell viability
• Real-world applications and benefits of lipid-based gene delivery versus traditional methods like electroporation and viral vectors
• Practical applications of non-viral delivery for gene-modified cell therapies including engineered T cells, NK cells and hematopoietic stem cells in key disease areas including cancer, autoimmune disease, and genetic disorders

Chesney Michels

Director of Emerging Tech and Innovation at ElevateBio

Dr Chesney Michels serves as Director of ElevateBio’s PD Platform and Emerging Technology team. He is focused on supporting clients with cells from pre-clinical development of NextGen therapeutics, and evaluating new process technologies, instruments and reagents that have the potential to disrupt the CGT space, from early stages through to commercialization.

Chesney has 10 years of analytical and process development experience collaboratively working with TechOps, MSAT, MFG and facility engineers to increase efficiency, reduce COGS and simplify workflows. Prior to working in private industry, Chesney worked many years in academia, investigating innate and adaptive immune cell trafficking in response to infectious and inflammatory diseases.

Claire Guéguen

R&D Life Sciences Manager at Sartorius Polyplus

Claire Guéguen serves as R&D Life Science Manager at Sartorius Polyplus. She earned her PhD in Immunology from the University of Paris-Saclay, in collaboration with Stallergenes Greer. Prio to joining Sartorius Polyplus, Claire spent five years at Adaptimmune in the R&D Department on TCR T-cell therapies and the generation of allogeneic T cells from iPSCs. At Sartorius Polyplus, she now leads the screening and development of innovative transfection reagents for in vitro and in vivo

nucleic acid delivery, with a focus on immune and stem cell transfection.

You have registered for this webinar

Watch now

SPEAKERS

Chesney Michels

Director of Emerging Tech and Innovation at ElevateBio

Claire Guéguen

R&D Life Sciences Manager at Sartorius Polyplus

You might also like

Targeting brain delivery of lipid and polymer nanoparticle-based gene therapies with Sunshine

B Knappett, N Bhingaradiya, M Dewani

26 June 2025

Watch

Improved gene delivery and T Cell editing using cell free DNA and novel non viral delivery solutions

Claire Gueguen, PhD, Peter Archibald, PhD

27 May

in 29

Days

Register

Advancing delivery of oligonucleotide therapeutics through next-generation delivery strategies and novel chemistries

S Dowdy, J Dahlman, K Ross

28 August 2025

Watch

Non-viral, large-scale delivery of gene editing tools for T cell manufacturing

Stefanie Müthel, Andrea Toell

18 September 2025

Watch